MIRA INFORM REPORT

 

 

Report Date :

02.05.2014              

 

IDENTIFICATION DETAILS

 

Name :

ALPS PHARMACEUTICAL IND CO LTD

 

 

Registered Office :

2-10-50 Mukaimachi Furukawacho Hida-she Gifu-Pref 509-4241

 

 

Country :

Japan

 

 

Financials (as on) :

31.03.2013

 

 

Date of Incorporation :

July 1947

 

 

Legal Form :

Limited Company (Kabushiki Kaisha)

 

 

Line of Business :

Manufacturing of medicines, industrial chemicals, food additives

 

 

No. of Employees

306

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

COMPANY NAME AND ADDRESS

 

ALPS PHARMACEUTICAL IND CO LTD

 

REGD NAME:   Alps Yakuhin Kogyo KK

MAIN OFFICE:  2-10-50 Mukaimachi Furukawacho Hida-she Gifu-Pref 509-4241 JAPAN

Tel: 0577-73-2021      Fax: 0577-74-0001

 

URL:                 http://www.alps-pharma.co.jp

E-Mail address: (thru the URL)

 

 

ACTIVITIES

 

Mfg of medicines, industrial chemicals, food additives

 

 

BRANCHES     

 

Tokyo, Osaka

 

 

OVERSEAS

 

China (partners)

 

 

FACTORIES

 

At the caption address, Toyama

 

 

OFFICERS       

 

OSAMU USHIMARU, PRES       Masaaki Yuzuhara, mgn dir

Yoshitaka Ota, dir                      Masanobu Okayama, dir

                       

Yen Amount:     In million Yen, unless otherwise stated

 

 

SUMMARY      

 

FINANCES        FAIR                 A/SALES          Yen 8,970 M

PAYMENTSNo Complaints        CAPITAL           Yen 97 M

TREND UP                    WORTH            Yen 5,825 M     

STARTED         1947                 EMPLOYES      306

 

 

COMMENT      

 

MFR OF PHARMACEUTICALS, CHEMICALS, FOOD ADDITIVES, OTHER.

FINANCIAL SITUATION CONSIDERED FAIR AND GOOD FOR ORDINARY BUSINESS ENGAGEMENTS.

                       

 

HIGHLIGHTS

           

The subject company is a specialized mfr of pharmaceuticals, originally starting as mfr of medicines from herbs, and later expanded into various pharmaceuticals: botanicals, kampo medicine, synthetic medicine, industrial chemicals, food additives, other (See OPERATION).  Raw materials are imported.  Products are exported widely.  Clients include major medicine mfrs, wholesalers, supermarkets, other.

 

 

FINANCIAL INFORMATION

           

The sales volume for Mar/2013 fiscal term amounted to Yen 8,970 million, a 2% up from Yen 8,820 million in the previous term.  The recurring profit was posted at Yen 860 million and the net profit at Yen 479 million, respectively, compared with Yen 603 million recurring profit and Yen 470 million net profit, respectively, a year ago.

 

For the term that ended Mar 2014 the recurring profit was projected at Yen 900 million and the net profit at Yen 500 million, respectively, on a 5% rise in turnover, to Yen 9,450 million.  Final results are yet to be released.

 

The financial situation is considered FAIR and good for ORDINARY business engagements. 

 

 

REGISTRATION

 

Date Registered:              Jul 1947

Legal Status:       Limited Company (Kabushiki Kaisha)

Authorized:         781,600 shares

Issued:                195,400 shares

Sum:                   Yen 97.7 million

      Major shareholders (%): Hiroshi Ogura (51.4), Employees’ S/Holding Assn (7.8), Kazuyuki Ogura (6.2), Yasuyuki Ogura (3.5)

      No. of shareholders: 12                                                                                                                                                                       

Nothing detrimental is known as to the commercial morality of executives.

 

 

OPERATION

           

Activities: Manufactures pharmaceutical raw materials, intermediates, food additives, food ingredients, veterinary pharmaceutical raw materials, feed additives, cosmetic ingredients, fertilizers & botanicals, food flavor, synthetic medicines, other (--100%)

 

Clients: [Mfrs, wholesalers] Taisho Pharmaceutical, Novaltis Animal Health KK, Rohto Pharmaceutical, Mitsubishi Tanabe Pharma, Mitsui & Co, Takeda Chemical Ind, other 

No. of accounts: 500

Domestic areas of activities: Nationwide

 

Suppliers: [Mfrs, wholesalers] Kowa Co (10%), Nisso Shoji Co (3%), Kongo Yakuhin (2%), Aoshima Taito Yakuhin (2%), other

 

Payment record: No Complaints

 

Location: Business area in Hida City, Gifu-Pref.  Office premises at the caption address are owned and maintained satisfactorily.

 

Bank References:

SMBC (Gifu)

Juroku Bank (Furukawa)

Relations: Satisfactory

 

 

FINANCES

 

 (In Million Yen)

       Terms Ending:

31/03/2014

31/03/2013

31/03/2012

31/03/2011

Annual Sales

　

9,450

8,970

8,820

8,185

Recur. Profit

　

900

860

603

　

Net Profit

　

500

479

470

235

Total Assets

　

　

15,539

14,558

13,649

Current Assets

　

　

9,772

9,439

　

Current Liabs

　

　

5,989

4,833

　

Net Worth

　

　

5,825

5,248

4,799

Capital, Paid-Up

　

　

97

97

97

Div.Ttl in Million (¥)

　

　

19.5

19.5

19.5

<Analytical Data>

(%)

(%)

(%)

(%)

    S.Growth Rate

5.35

1.70

7.76

1.99

    Current Ratio

..

163.17

195.30

..

    N.Worth Ratio

..

37.49

36.05

35.16

    R.Profit/Sales

9.52

9.59

6.84

..

    N.Profit/Sales

5.29

5.34

5.33

2.87

    Return On Equity

..

8.22

8.96

4.90

 

Notes: Forecast (or estimated) figures for the 31/03/2014 fiscal term.

 

               

RATING EXPLANATIONS

 

RATING

STATUS

PROPOSED CREDIT LINE

 

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

 

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

 

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

 

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

 

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

 

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

 

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

Credit not recommended

 

--

NB

New Business

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                  Payment record (10%)

Credit history (10%)                   Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.